HTG Molecular Diagnostics (NASDAQ:HTGM)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, TipRanks reports. They presently have a $2.00 price objective on the medical research company’s stock. HC Wainwright’s price objective would indicate a potential upside of 185.71% from the company’s previous close.
A number of other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of HTG Molecular Diagnostics in a research report on Friday, October 18th. ValuEngine raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Canaccord Genuity set a $1.50 target price on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Thursday, September 26th. Finally, Craig Hallum set a $3.00 target price on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Friday, September 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $3.10.
Shares of HTGM stock opened at $0.70 on Wednesday. The firm has a fifty day moving average of $0.81 and a 200-day moving average of $1.42. The company has a quick ratio of 3.34, a current ratio of 3.49 and a debt-to-equity ratio of 0.87. HTG Molecular Diagnostics has a 12-month low of $0.60 and a 12-month high of $3.90. The company has a market capitalization of $44.96 million, a price-to-earnings ratio of -1.17 and a beta of 1.68.
A number of institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. increased its stake in HTG Molecular Diagnostics by 297.1% in the third quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research company’s stock valued at $1,564,000 after acquiring an additional 1,760,533 shares during the period. Citadel Advisors LLC increased its stake in HTG Molecular Diagnostics by 153.9% in the second quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 23,351 shares during the period. Vanguard Group Inc. increased its stake in HTG Molecular Diagnostics by 20.0% in the second quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after acquiring an additional 242,497 shares during the period. BlackRock Inc. grew its stake in HTG Molecular Diagnostics by 504.3% during the second quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock worth $673,000 after buying an additional 338,681 shares during the last quarter. Finally, Alambic Investment Management L.P. bought a new stake in HTG Molecular Diagnostics during the second quarter worth about $38,000. 27.20% of the stock is owned by institutional investors and hedge funds.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.